Table 1 Baseline participant demographics and characteristics (PD analysis set, n = 31)
From: Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial
Parameter | All patients (n = 31) |
|---|---|
Age (median [range]), year | 68.0 (53–76) |
Sex, n (%) | |
 Male | 16 (51.6) |
Body mass index (mean [SD]), kg/m2 | 26.53 (4.49) |
Race, n (%) | |
 Caucasian | 31 (100.0) |
Severity of COPD—airflow limitationa, n (%) | |
 Moderate (GOLD 2) | 21 (67.7) |
 Severe (GOLD 3) | 10 (32.3) |
Lung function (post-bronchodilatorb) (mean [SD]) | |
 FEV1, % predicted | 53.1 (11.68) |
 FEV1/FVC, % | 46.4 (8.82) |
 Residual volume, L | 2.9 (0.8) |
 Inspiratory capacity, L | 2.2 (0.56) |
Ventilated lung volume (mean [SD]), % | 55.42 (19.85) |
Degree of emphysema at screening (mean [SD]), % | 10.14 (7.35) |